ClinicalTrials.gg
CompletedNCT03110380Updated Jan 11, 2022Results posted

Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Adults Who Are Virologically Suppressed

A Phase 3 interventional study of B/F/TAF and F/TAF in HIV-1-infection, sponsored by Gilead Sciences. Completed at 94 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-01-11.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
567
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The primary objective of this study is to evaluate the efficacy of switching from a regimen of either dolutegravir (DTG) and emtricitabine /tenofovir alafenamide (F/TAF) or DTG and emtricitabine/tenofovir disoproxil fumarate (F/TDF) to a fixed dose combination (FDC) of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus DTG+F/TAF in virologically suppressed HIV-1 infected adults with or without antiretroviral (ARV) resistance.

02

Conditions studied

  • HIV-1-infection
03

In context

Lead sponsor

Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.

Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Currently receiving an ARV regimen of DTG+F/TAF or DTG+F/TDF for the following minimum time periods:

    • ≥ 6 months (if there is documented or suspected nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) resistance prior to the screening visit)
    • ≥ 3 months (if there is no documented or suspected NRTI resistance prior to the screening visit)
  • Documented plasma -1 ribonucleic acid (RNA) \< 50 copies/mL during treatment with DTG+F/TAF or DTG+F/TDF (for a minimum period of ≥ 6 or ≥ 3 months, as applicable) preceding the screening visit
  • Plasma HIV-1 RNA levels \< 50 copies/mL at screening visit
  • Estimated (eGFR) ≥ 30 mL/min according to the formula for creatinine clearance
  • No documented resistance to integrase stand transfer inhibitors (INSTIs) or confirmed virologic failure
  • Eligible adults with chronic virus (HBV) and/or virus (HCV) infection are permitted to enroll

NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
567 participants (actual)

Study arms

  • Experimental
    B/F/TAF

    Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) fixed-dose combination (FDC) tablet + dolutegravir (DTG) placebo tablet + emtricitabine/tenofovir alafenamide (F/TAF) placebo tablet administered without regard to food for at least 48 weeks.

    Drug: B/F/TAF · Drug: DTG Placebo · Drug: F/TAF Placebo

  • Active comparator
    DTG + F/TAF

    DTG 50 mg tablet + F/TAF FDC tablet + B/F/TAF placebo tablet administered without regard to food for at least 48 weeks.

    Drug: F/TAF · Drug: DTG · Drug: B/F/TAF Placebo

  • Experimental
    Open-label Phase B/F/TAF from B/F/TAF

    Participants who received B/F/TAF in double-blind phase and from a country where B/F/TAF was not available were given the option to receive B/F/TAF orally once daily for up to 96 weeks in the open-label extension phase.

    Drug: B/F/TAF

  • Experimental
    Open-label Phase B/F/TAF from DTG + F/TAF

    Participants who received DTG + F/TAF in double-blind phase and from a country where B/F/TAF was not available were given the option to receive B/F/TAF orally once daily for up to 96 weeks in the open-label extension phase.

    Drug: B/F/TAF

Interventions

  • DrugB/F/TAF

    Drug pages: Bictegravir · Emtricitabine · Tenofovir alafenamide

    50/200/25 mg FDC tablet(s) administered orally once daily

    Also known as: GS-9883/F/TAF, Biktarvy®

  • DrugF/TAF

    Drug pages: Emtricitabine · Tenofovir alafenamide

    200/25 mg FDC tablet(s) administered orally once daily

    Also known as: Descovy®

  • DrugDTG

    50 mg tablet(s) administered orally once daily

    Also known as: Tivicay®

  • DrugDTG Placebo

    Tablet(s) administered orally once daily

  • DrugF/TAF Placebo

    Tablet(s) administered orally once daily

  • DrugB/F/TAF Placebo

    Tablet(s) administered orally once daily

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm

    The percentage of participants with HIV-1 RNA ≥ 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 48

Secondary outcomes

  1. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm

    The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 48

  2. Change From Baseline in CD4+ Cell Count at Week 48

    Time frame: Baseline; Week 48

07

Results

Posted Nov 20, 2019

Participant flow

Participants were enrolled at study sites in North America and Europe. The first participant was screened on 12 June 2017. The last study visit occurred on 10 Feb 2021.

Double-Blind Treatment Phase
Participant flow — Double-Blind Treatment Phase
MilestoneB/F/TAFDTG + F/TAFB/F/TAF From B/F/TAFB/F/TAF From DTG + F/TAF
Started28428300
Safety analysis set28428100
Completed26325300
Not completed213000
Withdrew: Withdrew consent101600
Withdrew: Lost to follow-up4300
Withdrew: Adverse event3300
Withdrew: Investigator's discretion1300
Withdrew: Death2100
Withdrew: Non-compliance with study drug1100
Withdrew: Protocol violation0100
Withdrew: Randomized but not treated0200
Open-label B/F/TAF Extension Phase
Participant flow — Open-label B/F/TAF Extension Phase
MilestoneB/F/TAFDTG + F/TAFB/F/TAF From B/F/TAFB/F/TAF From DTG + F/TAF
Started00125116
Completed00121113
Not completed0043
Withdrew: Lost to follow-up0031
Withdrew: Withdrew consent0011
Withdrew: Adverse event0001

Outcome measures

PrimaryPercentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm

The percentage of participants with HIV-1 RNA ≥ 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm
percentage of participantsB/F/TAFDTG + F/TAF
Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm0.41.1
Statistical analysis
  • B/F/TAF vs DTG + F/TAF · Difference in percentages: -0.7 · 95.001% CI -2.8 to 1.0The differences in percentages of participants between treatment groups and their 95.001% confidence intervals (CI) were calculated based on an unconditional exact method using 2 inverted 1-sided tests.
  • B/F/TAF vs DTG + F/TAF · Fisher Exact · p = 0.37
SecondaryPercentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm

The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm
percentage of participantsB/F/TAFDTG + F/TAF
Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm93.391.1
Statistical analysis
  • B/F/TAF vs DTG + F/TAF · Difference in percentages: 2.2 · 95.001% CI -2.3 to 6.8The differences in percentages of participants between treatment groups and their 95.001% CI were calculated based on an unconditional exact method using 2 inverted 1-sided tests.
SecondaryChange From Baseline in CD4+ Cell Count at Week 48
Time frame:
Baseline; Week 48
Reported as:
Mean · cells/µL
Change From Baseline in CD4+ Cell Count at Week 48
cells/µLB/F/TAFDTG + F/TAF
Change From Baseline in CD4+ Cell Count at Week 4818 ± 179.136 ± 152.6
Statistical analysis
  • B/F/TAF vs DTG + F/TAF · ANOVA · p = 0.23 · Difference in lsm: -18 · 95% CI -46 to 11P-value, difference in least squares means (LSM), and its 95% CI were from ANOVA model with treatment group as a fixed effect in the model.

Adverse events

Collected over Adverse Events: First dose date up to last dose date [maximum: 84.9 weeks (Blinded Phase), 179.6 weeks (Open Label Phase) plus 30 days All-Cause Mortality: Randomization/Enrollment up to 187.7 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Double-Blind Treatment Phase B/F/TAF3/284 (1.1%)36/284 (12.7%)181/284 (63.7%)
Double-Blind Treatment Phase DTG + F/TAF2/283 (0.7%)27/281 (9.6%)170/281 (60.5%)
Open-label Extension Phase B/F/TAF From B/F/TAF0/125 (0%)12/125 (9.6%)30/125 (24%)
Open-label Extension Phase B/F/TAF From DTG + F/TAF0/117 (0%)11/116 (9.5%)33/116 (28.4%)
Most frequent serious events
Showing 10 of 89
Most frequent serious events
EventDouble-Blind Treatment Phase B/F/TAFDouble-Blind Treatment Phase DTG + F/TAFOpen-label Extension Phase B/F/TAF From B/F/TAFOpen-label Extension Phase B/F/TAF From DTG + F/TAF
PneumoniaInfections and infestations1/2842/2810/1252/116
Acute myocardial infarctionCardiac disorders0/2840/2812/1250/116
Lymphocytic infiltrationBlood and lymphatic system disorders0/2840/2810/1251/116
Abdominal painGastrointestinal disorders0/2841/2810/1251/116
Chest painGeneral disorders1/2840/2811/1251/116
Non-cardiac chest painGeneral disorders0/2840/2810/1251/116
Cholangitis acuteHepatobiliary disorders0/2840/2810/1251/116
Anti-neutrophil cytoplasmic antibody positive vasculitisImmune system disorders0/2840/2810/1251/116
Colonic abscessInfections and infestations0/2840/2810/1251/116
EpididymitisInfections and infestations0/2840/2810/1251/116
Most frequent other events
Showing 10 of 15
Most frequent other events
EventDouble-Blind Treatment Phase B/F/TAFDouble-Blind Treatment Phase DTG + F/TAFOpen-label Extension Phase B/F/TAF From B/F/TAFOpen-label Extension Phase B/F/TAF From DTG + F/TAF
NasopharyngitisInfections and infestations44/28432/2813/1251/116
Upper respiratory tract infectionInfections and infestations33/28440/2819/12510/116
DiarrhoeaGastrointestinal disorders26/28435/2814/1257/116
ArthralgiaMusculoskeletal and connective tissue disorders24/28421/2814/1254/116
HeadacheNervous system disorders16/28423/2811/1254/116
FatigueGeneral disorders22/2849/2811/1257/116
Back painMusculoskeletal and connective tissue disorders20/28415/2812/1253/116
InfluenzaInfections and infestations19/28417/2812/1251/116
InsomniaPsychiatric disorders19/28414/2811/1253/116
BronchitisInfections and infestations18/28414/2814/1255/116

Baseline characteristics

The Safety Analysis Set included participants who were randomized and received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)B/F/TAFDTG + F/TAFTotal
Mean50 ± 11.349 ± 11.350 ± 11.3
Sex: Female, Male
Sex: Female, Male(Participants)B/F/TAFDTG + F/TAFTotal
Female394180
Male245240485
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)B/F/TAFDTG + F/TAFTotal
Race — American Indian or Alaska Native011
Race — Asian336
Race — Black6861129
Race — Native Hawaiian or Pacific Islander213
Race — White200199399
Race — Other91322
Race — Not Permitted235
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)B/F/TAFDTG + F/TAFTotal
Ethnicity — Hispanic or Latino6149110
Ethnicity — Not Hispanic or Latino220229449
Ethnicity — Not Permitted336
Region of Enrollment
Region of Enrollment(Participants)B/F/TAFDTG + F/TAFTotal
Canada242549
Austria213
United States197202399
France121426
Germany302656
Puerto Rico191332
HIV-1 RNA Category
HIV-1 RNA Category(Participants)B/F/TAFDTG + F/TAFTotal
< 50 copies/mL276275551
≥ 50 copies/mL8614
CD4 Cell Count
CD4 Cell Count(Cells/μL)B/F/TAFDTG + F/TAFTotal
Mean714 ± 309.1658 ± 294.7686 ± 303.1
CD4 Cell Count Category
CD4 Cell Count Category(Participants)B/F/TAFDTG + F/TAFTotal
< 50 Cells/ μL011
≥ 50 to < 200 Cells/μL6612
≥ 200 to < 350 Cells/μL183452
≥ 350 to < 500 Cells/μL534497
≥ 500 Cells/ μL207196403
08

Study locations

94 sites
  • Spectrum Medical Group
    Phoenix, Arizona 85012, United States
  • Ruane Clinical Research Group Inc.
    Los Angeles, California 90036, United States
  • Mills Clinical Research
    Los Angeles, California 90069, United States
  • Highland Hospital - Alameda Health System
    Oakland, California 94602, United States
  • Cares Community Health
    Sacramento, California 95814, United States
  • Kaiser Permanente
    Sacramento, California 95825, United States
  • Hepatitis/HIV Clinical Trials Group (HHCTG)
    San Francisco, California 94110, United States
  • Kaiser Permanente
    San Francisco, California 94118, United States
  • Kaiser Permanente, Department of Infectious Diseases
    San Leandro, California 94577, United States
  • University of Colorado Denver, University of Colorado Hospital
    Aurora, Colorado 80045, United States
  • Whitman-Walker Institute
    Washington, District of Columbia 20005, United States
  • Dupont Circle Physician's Group
    Washington, District of Columbia 20009, United States
  • Providence Hospital Center for Infectious Diseases
    Washington, District of Columbia 20017, United States
  • The GW Medical Faculty Associates
    Washington, District of Columbia 20037, United States
  • Midland Florida Clinical Research Center, LLC
    DeLand, Florida 32720, United States
  • Therafirst Medical Center
    Fort Lauderdale, Florida 33308, United States
  • Gary J. Richmond, M.D., P.A.
    Fort Lauderdale, Florida 33316, United States
  • Midway Immunology and Research Center
    Fort Pierce, Florida 34982, United States
  • AIDS Healthcare Foundation - South Beach
    Miami Beach, Florida 33140, United States
  • University of Miami Divison of Infectious Diseases Clinical Research Unit
    Miami, Florida 33136, United States
  • Orlando Immunology Center
    Orlando, Florida 32803, United States
  • AHF-Pensacola
    Pensacola, Florida 32503, United States
  • Infectious Disease Research Institute Inc
    Tampa, Florida 33614, United States
  • St. Joseph's Hospital Comprehensive Research Institute
    Tampa, Florida 33614, United States
  • AIDS Research and Treatment Center of the Treasure Coast
    Vero Beach, Florida 32960, United States
  • Triple O Research Institute, P.A.
    West Palm Beach, Florida 33407, United States
  • Emory Hospital Midtown Infectious Disease Clinic
    Atlanta, Georgia 30308, United States
  • AIDS Research Consortium of Atlanta
    Atlanta, Georgia 30312, United States
  • AU Medical Center
    Augusta, Georgia 30912, United States
  • Infectious Disease Specialists of Atlanta
    Decatur, Georgia 30033, United States
  • Mercer University, Department of Internal Medicine
    Macon, Georgia 31201, United States
  • Chatham County Health Department
    Savannah, Georgia 31401, United States
  • John A. Burns School of Medicine, University of Hawaii Clinics at Kaka'ako
    Honolulu, Hawaii 96813, United States
  • University of Louisville 550 Clinic
    Louisville, Kentucky 40202, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • Boston Medical Center
    Boston, Massachusetts 02118, United States
  • Community Research Initiative of New England
    Boston, Massachusetts 02129, United States
  • Metro West Medical Center
    Framingham, Massachusetts 01702, United States
  • Claudia T Martorell, MD., LLC d/b/a The Research Institute
    Springfield, Massachusetts 01105, United States
  • Be Well Medical Center
    Berkley, Michigan 48072, United States
  • Abbott Northwestern Hospital part of Allina Health
    Minneapolis, Minnesota 55407, United States
  • Hennepin County Medical Center, Positive Care Clinic
    Minneapolis, Minnesota 55415, United States
  • Kansas City CARE Clinic
    Kansas City, Missouri 64111, United States
  • Southampton Healthcare, Inc.
    Saint Louis, Missouri 63139, United States
  • Prime Healthcare Services - St. Michael's LLC d/b/a Saint Michael's Medical Center
    Newark, New Jersey 07102, United States
  • Southwest CARE Center
    Albuquerque, New Mexico 87109, United States
  • Southwest CARE Center
    Santa Fe, New Mexico 87505, United States
  • Jacobi Medical Center
    Bronx, New York 10461, United States
  • Montefiore Medical Center
    Bronx, New York 10467, United States
  • North Shore University Hospital/Division of Infectious Diseases
    Manhasset, New York 11030, United States
  • NC TraCS Institute - CTRC; University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27514, United States
  • Duke University Heath System
    Durham, North Carolina 27710, United States
  • East Carolina University (ECU), The Brody School of Medicine, Adult Specialty Care
    Greenville, North Carolina 27834, United States
  • Rosedale Infectious Diseases
    Huntersville, North Carolina 28078, United States
  • Wake Forest Baptist Health
    Winston-Salem, North Carolina 27157, United States
  • Medical University of South Carolina (MUSC)
    Charleston, South Carolina 29425, United States
  • Palmetto Health Richland (Regulatory and Study Supply Shipping)
    Columbia, South Carolina 29203, United States
  • Central Texas Clinical Research
    Austin, Texas 78705, United States
  • AIDS Arms Inc/ Trinity Health and Wellness Center
    Dallas, Texas 75208, United States
  • North Texas Infectious Diseases Consultants, P.A.
    Dallas, Texas 75246, United States
  • Therapeutic Concepts, PA
    Houston, Texas 77004, United States
  • Research Access Network
    Houston, Texas 77098, United States
  • The Crofoot Research Center, INC (DBA: Gordon E. Crofoot MD PA)
    Houston, Texas 77098, United States
  • DCOL Center for Clinical Research
    Longview, Texas 75605, United States
  • Peter Shalit, M.D.
    Seattle, Washington 98104, United States
  • MultiCare Rockwood HIV Critical Care Clinic
    Spokane, Washington 99204, United States
  • Medizinische Universitat Wien, Universitatsklinik fur Dermatologie
    Wien, 1090, Austria
  • Kaye Edmonton Clinic
    Edmonton, Alberta T6G 2G3, Canada
  • Spectrum Health Clinic
    Vancouver, British Columbia 6Z 2T1, Canada
  • Winnipeg Regional Health Authority - Health Sciences Centre Winnipeg
    Winnipeg, Manitoba R3A 1R9, Canada
  • Maple Leaf Research / Maple Leaf Medical Clinic
    Toronto, Ontario M5G 1K2, Canada
  • Clinique de Médecine Urbaine du Quartier Latin
    Montréal, Quebec H2L 5B1, Canada
  • Chronical Viral Illness Service/McGill University Health Care (MUHC)
    Montréal, Quebec H4A 3J1, Canada
  • Hôpital Saint-André
    Bordeaux, 33075, France
  • Hôpital Croix-Rousse
    Lyon, 69004, France
  • Hôpital Gui de Chauliac, CHU de Montpellier
    Montpellier, 34295, France
  • CHU de Nice-l'Archet
    Nice, 06202, France
  • CHU Bichat
    Paris, 75018, France
  • AP-HP Hôpital Tenon
    Paris, 75020, France
  • Hôpital Saint-Louis
    Paris, 75475, France
  • Hôpital Saint-Antoine
    Paris, 75571, France
  • zibp Zentrum für Infektiologie Berlin Prenzlauer Berg
    Berlin, 10439, Germany
  • EPIMED Gesellschaft fur epidemiologische und klinische Forschung in der Medizin mbH
    Berlin, 12157, Germany
  • Universitätsklinikum Bonn, Medizinische Klinik und Poliklinik I, Klinisches Studienzentrum Immunologie
    Bonn, 53127, Germany
  • Universitätsklinikum Köln - Klinik I fur Innere Medizin - Klinisches Studienzentrum fur Infektiologie I
    Cologne, 50937, Germany
  • Universitätsklinikum Essen - Klinik fur Dermatologie und Venerologie - HPSTD Ambulanz
    Essen, 45122, Germany
  • Universitätsklinikum Frankfurt, Medizinische Klinik II, Schwerpunkt Infektiologie, Haus 68
    Frankfurt am Main, 60590, Germany
  • Infektiologikum Frankfurt
    Frankfurt am Main, 60596, Germany
  • ICH Study Center GmbH & Co. KG
    Hamburg, 20146, Germany
  • Universitätsklinikum Hamburg- Eppendorf - Ambulanzzentrum des Universitatsklinikums Eppendorf GmbH - Bereich Infektiologie
    Hamburg, 20246, Germany
  • Instituto de Investigacion Cientifica del Sur
    Ponce, 00730, Puerto Rico
  • Hope Clinical Research
    San Juan, 00909, Puerto Rico
  • Proyecto ACTU
    San Juan, 00935, Puerto Rico
  • Clinical Research Puerto Rico
    San Juan, 909, Puerto Rico
09

References and documents

Publications

  • Sax PE, Rockstroh JK, Luetkemeyer AF, Yazdanpanah Y, Ward D, Trottier B, Rieger A, Liu H, Acosta R, Collins SE, Brainard DM, Martin H; GS-US-380-4030 Investigators. Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus. Clin Infect Dis. 2021 Jul 15;73(2):e485-e493. doi: 10.1093/cid/ciaa988. PubMed 32668455 ↗
  • Acosta RK, Willkom M, Andreatta K, Liu H, Martin R, Parvangada A, Martin H, Collins S, White KL. Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance. J Acquir Immune Defic Syndr. 2020 Nov 1;85(3):363-371. doi: 10.1097/QAI.0000000000002454. PubMed 32701823 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gilead.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2017 to primary completion in Dec 2018, 17 months.

Results were first posted in Nov 2019, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2017
First posted
Apr 12, 2017
StartActual
Jun 12, 2017
Primary completionActual
Dec 4, 2018
CompletionActual
Feb 10, 2021
Results first posted
Nov 20, 2019
Last update
Jan 11, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 11, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03110380
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Apr 12, 2017
Start date
Jun 12, 2017
Primary completion
Dec 4, 2018
Completion
Feb 10, 2021
Results posted
Nov 20, 2019
Last update
Jan 11, 2022

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bictegravir · Emtricitabine · Tenofovir alafenamide

Start the discussion